Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $4,158,442.34 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 109,031 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the sale, the executive vice president directly owned 4,000 shares in the company, valued at $152,560. This trade represents a 96.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Simrat Randhawa also recently made the following trade(s):

• On Thursday, November 13th, Simrat Randhawa sold 87,507 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $36.81, for a total value of $3,221,132.67.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock opened at $40.85 on Monday. The stock has a market cap of $1.75 billion, a PE ratio of -11.74 and a beta of 1.56. The firm has a fifty day moving average price of $35.94 and a 200 day moving average price of $25.67. Dianthus Therapeutics, Inc. has a 1 year low of $13.36 and a 1 year high of $41.15.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The firm had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.58 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. As a group, equities analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on DNTH shares. Truist Financial began coverage on Dianthus Therapeutics in a report on Tuesday, October 14th. They set a “buy” rating and a $56.00 target price for the company. Raymond James Financial reissued an “outperform” rating and issued a $63.00 price objective (up from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday, September 9th. HC Wainwright raised their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a report on Monday, November 10th. Wedbush increased their target price on shares of Dianthus Therapeutics from $44.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Finally, Guggenheim boosted their price target on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, September 9th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $63.43.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Parkside Financial Bank & Trust grew its stake in shares of Dianthus Therapeutics by 131.7% during the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 540 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter worth about $27,000. US Bancorp DE increased its holdings in shares of Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock valued at $29,000 after acquiring an additional 1,510 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth about $64,000. Finally, Tower Research Capital LLC TRC lifted its stake in Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after purchasing an additional 3,317 shares during the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.